• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用阳离子 DNA 脂质体复合物结合细菌抗原,实现对毒力细菌感染的有效、广谱控制。

Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

机构信息

Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana, United States of America.

出版信息

PLoS Pathog. 2010 May 27;6(5):e1000921. doi: 10.1371/journal.ppat.1000921.

DOI:10.1371/journal.ppat.1000921
PMID:20523903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2877747/
Abstract

Protection against virulent pathogens that cause acute, fatal disease is often hampered by development of microbial resistance to traditional chemotherapeutics. Further, most successful pathogens possess an array of immune evasion strategies to avoid detection and elimination by the host. Development of novel, immunomodulatory prophylaxes that target the host immune system, rather than the invading microbe, could serve as effective alternatives to traditional chemotherapies. Here we describe the development and mechanism of a novel pan-anti-bacterial prophylaxis. Using cationic liposome non-coding DNA complexes (CLDC) mixed with crude F. tularensis membrane protein fractions (MPF), we demonstrate control of virulent F. tularensis infection in vitro and in vivo. CLDC+MPF inhibited bacterial replication in primary human and murine macrophages in vitro. Control of infection in macrophages was mediated by both reactive nitrogen species (RNS) and reactive oxygen species (ROS) in mouse cells, and ROS in human cells. Importantly, mice treated with CLDC+MPF 3 days prior to challenge survived lethal intranasal infection with virulent F. tularensis. Similarly to in vitro observations, in vivo protection was dependent on the presence of RNS and ROS. Lastly, CLDC+MPF was also effective at controlling infections with Yersinia pestis, Burkholderia pseudomallei and Brucella abortus. Thus, CLDC+MPF represents a novel prophylaxis to protect against multiple, highly virulent pathogens.

摘要

针对导致急性、致命疾病的烈性病原体的保护常常受到微生物对传统化疗药物产生耐药性的阻碍。此外,大多数成功的病原体拥有一系列免疫逃避策略,以避免被宿主检测和消除。开发针对宿主免疫系统而非入侵微生物的新型免疫调节性预防措施,可以作为传统化疗的有效替代方法。在这里,我们描述了一种新型广谱抗细菌预防措施的开发和机制。我们使用阳离子脂质体非编码 DNA 复合物 (CLDC) 与粗制土拉弗朗西斯菌膜蛋白部分 (MPF) 混合,证明了其在体外和体内控制烈性土拉弗朗西斯菌感染的能力。CLDC+MPF 在体外抑制了原代人源和鼠源巨噬细胞中的细菌复制。在小鼠细胞中,感染的控制是通过活性氮 (RNS) 和活性氧 (ROS) 介导的,而在人源细胞中则是通过 ROS 介导的。重要的是,在挑战前 3 天用 CLDC+MPF 处理的小鼠能够存活致命的鼻内烈性土拉弗朗西斯菌感染。与体外观察结果相似,体内保护依赖于 RNS 和 ROS 的存在。最后,CLDC+MPF 还能有效控制鼠疫耶尔森菌、鼻疽伯克霍尔德菌和流产布鲁氏菌的感染。因此,CLDC+MPF 代表了一种针对多种高致病性病原体的新型预防措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/b28c935d3aba/ppat.1000921.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/9894a72070ad/ppat.1000921.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/3f6791bb50d7/ppat.1000921.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/1354b68f6357/ppat.1000921.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/3bd0802b8994/ppat.1000921.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/80104222367a/ppat.1000921.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/3e75d0b6a773/ppat.1000921.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/b28c935d3aba/ppat.1000921.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/9894a72070ad/ppat.1000921.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/3f6791bb50d7/ppat.1000921.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/1354b68f6357/ppat.1000921.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/3bd0802b8994/ppat.1000921.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/80104222367a/ppat.1000921.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/3e75d0b6a773/ppat.1000921.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e1/2877747/b28c935d3aba/ppat.1000921.g007.jpg

相似文献

1
Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.利用阳离子 DNA 脂质体复合物结合细菌抗原,实现对毒力细菌感染的有效、广谱控制。
PLoS Pathog. 2010 May 27;6(5):e1000921. doi: 10.1371/journal.ppat.1000921.
2
Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.用于预防土拉弗朗西斯菌肺炎感染的黏膜免疫疗法。
Vaccine. 2009 Jul 16;27(33):4424-33. doi: 10.1016/j.vaccine.2009.05.041. Epub 2009 May 31.
3
Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections.鼻用 Acai 多糖增强固有免疫以预防肺部感染弗朗西斯菌和类鼻疽伯克霍尔德菌。
PLoS Pathog. 2012;8(3):e1002587. doi: 10.1371/journal.ppat.1002587. Epub 2012 Mar 15.
4
Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei.新型工程化阳离子抗菌肽对土拉弗朗西斯菌、鼠疫耶尔森菌和类鼻疽伯克霍尔德菌具有广谱活性。
J Med Microbiol. 2016 Feb;65(2):188-194. doi: 10.1099/jmm.0.000209. Epub 2015 Dec 15.
5
Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.通过吸入免疫疗法预防伯克霍尔德菌属引起的肺部感染。
Infect Immun. 2009 Apr;77(4):1579-88. doi: 10.1128/IAI.01384-08. Epub 2009 Jan 29.
6
Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection.非奈利酮对感染小鼠模型中的吸入性土拉菌病和鼠疫是一种有效的治疗方法。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02294-20.
7
Characterization of a Unique Outer Membrane Protein Required for Oxidative Stress Resistance and Virulence of Francisella tularensis.鉴定一种独特的外膜蛋白对于土拉弗朗西斯菌的氧化应激抗性和毒力的必要性。
J Bacteriol. 2018 Mar 26;200(8). doi: 10.1128/JB.00693-17. Print 2018 Apr 15.
8
Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species.确认图拉弗朗西斯菌活疫苗株的铜锌超氧化物歧化酶对抵抗细胞外产生的活性氧至关重要。
J Bacteriol. 2009 Oct;191(20):6447-56. doi: 10.1128/JB.00534-09. Epub 2009 Aug 14.
9
The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studies.费希尔 344 大鼠反映了人类对弗朗西斯菌肺部挑战的易感性,并为毒力和保护研究提供了一个新的平台。
PLoS One. 2010 Apr 1;5(4):e9952. doi: 10.1371/journal.pone.0009952.
10
Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.土拉热弗朗西斯菌活疫苗株中减毒嘌呤营养缺陷型菌株的构建与鉴定
Infect Immun. 2006 Aug;74(8):4452-61. doi: 10.1128/IAI.00666-06.

引用本文的文献

1
Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets against : an approach.基于外膜蛋白开发多表位疫苗及鉴定新型药物靶点:一种方法
Front Immunol. 2025 Apr 3;16:1479862. doi: 10.3389/fimmu.2025.1479862. eCollection 2025.
2
Evaluation of immunogenicity and protective efficacy of a liposome containing Brucella abortus S19 outer membrane protein in BALB/c mice.含流产布鲁氏菌S19外膜蛋白脂质体在BALB/c小鼠中的免疫原性和保护效果评估。
Iran J Vet Res. 2016 Winter;17(1):1-7.
3
Francisella tularensis LVS surface and membrane proteins as targets of effective post-exposure immunization for tularemia.

本文引用的文献

1
CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.CpG寡脱氧核糖核苷酸可保护小鼠免受类鼻疽伯克霍尔德菌感染,但对土拉弗朗西斯菌Schu S4气溶胶无效。
J Immune Based Ther Vaccines. 2010 Feb 5;8(1):2. doi: 10.1186/1476-8518-8-2.
2
The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo.CD14 的存在克服了毒力弗朗西斯菌在体外人树突状细胞和体内肺细胞中逃避先天免疫反应的能力。
Infect Immun. 2010 Jan;78(1):154-67. doi: 10.1128/IAI.00750-09. Epub 2009 Oct 19.
3
土拉热弗朗西斯菌弱毒株表面蛋白和膜蛋白作为兔热病暴露后有效免疫的靶点
J Proteome Res. 2015 Feb 6;14(2):664-75. doi: 10.1021/pr500628k. Epub 2014 Dec 29.
4
Control of intracellular Francisella tularensis by different cell types and the role of nitric oxide.不同细胞类型对细胞内弗朗西斯氏土拉菌的控制和一氧化氮的作用。
J Immunol Res. 2014;2014:694717. doi: 10.1155/2014/694717. Epub 2014 Jul 21.
5
Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?单核细胞/巨噬细胞对抗土拉弗朗西斯菌感染的炎症反应途径:可能的治疗靶点?
Front Cell Infect Microbiol. 2014 Feb 21;4:18. doi: 10.3389/fcimb.2014.00018. eCollection 2014.
6
Immunotherapy for tularemia.土拉菌病的免疫疗法。
Virulence. 2013 Nov 15;4(8):859-70. doi: 10.4161/viru.25454. Epub 2013 Jun 19.
7
Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α.来自强毒土拉弗朗西斯菌的脂质通过Toll样受体2和过氧化物酶体增殖物激活受体α广泛抑制肺部炎症。
Clin Vaccine Immunol. 2013 Oct;20(10):1531-40. doi: 10.1128/CVI.00319-13. Epub 2013 Aug 7.
8
Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8.土拉弗朗西斯菌 SchuS4 和 SchuS4 脂质通过抑制 IRF1 和 IRF8 抑制原代人树突状细胞中的 IL-12p40。
J Immunol. 2013 Aug 1;191(3):1276-86. doi: 10.4049/jimmunol.1300867. Epub 2013 Jul 1.
9
The stimulated innate resistance event in Bordetella pertussis infection is dependent on reactive oxygen species production.百日咳博德特氏菌感染中被刺激的固有抵抗力事件依赖于活性氧的产生。
Infect Immun. 2013 Jul;81(7):2371-8. doi: 10.1128/IAI.00336-13. Epub 2013 Apr 29.
10
B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.B1a 细胞通过调节 NK/NKT 细胞反应增强对毒力弗朗西斯菌感染的易感性。
J Immunol. 2013 Mar 15;190(6):2756-66. doi: 10.4049/jimmunol.1202697. Epub 2013 Feb 1.
Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.
用于预防土拉弗朗西斯菌肺炎感染的黏膜免疫疗法。
Vaccine. 2009 Jul 16;27(33):4424-33. doi: 10.1016/j.vaccine.2009.05.041. Epub 2009 May 31.
4
Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis.CD45蛋白酪氨酸磷酸酶的表达降低可预防炭疽发病机制。
J Biol Chem. 2009 May 8;284(19):12874-85. doi: 10.1074/jbc.M809633200. Epub 2009 Mar 6.
5
Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge.土拉弗朗西斯菌脂多糖诱导产生的抗原特异性B-1a抗体可提供针对土拉弗朗西斯菌LVS攻击的长期保护。
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4343-8. doi: 10.1073/pnas.0813411106. Epub 2009 Feb 26.
6
Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.通过吸入免疫疗法预防伯克霍尔德菌属引起的肺部感染。
Infect Immun. 2009 Apr;77(4):1579-88. doi: 10.1128/IAI.01384-08. Epub 2009 Jan 29.
7
Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4.强毒土拉弗朗西斯菌Schu S4对人树突状细胞功能的直接和间接损害
Infect Immun. 2009 Jan;77(1):180-95. doi: 10.1128/IAI.00879-08. Epub 2008 Nov 3.
8
Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.吸入土拉弗朗西斯菌Schu S4、LVS或U112后肺部受感染宿主细胞组成及细胞反应
Infect Immun. 2008 Dec;76(12):5843-52. doi: 10.1128/IAI.01176-08. Epub 2008 Oct 13.
9
The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression.土拉弗朗西斯菌的早期吞噬体阶段决定了最佳的吞噬体逃逸及土拉弗朗西斯菌致病岛蛋白表达。
Infect Immun. 2008 Dec;76(12):5488-99. doi: 10.1128/IAI.00682-08. Epub 2008 Oct 13.
10
Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs.阳离子脂质体 - DNA 复合物预防可保护仓鼠免受静脉病毒疾病侵害:脂质体递送和 CpG 基序的重要性。
Antiviral Res. 2009 Jan;81(1):37-46. doi: 10.1016/j.antiviral.2008.09.001. Epub 2008 Oct 7.